---
title: "Tharimmune Inc. Files Initial Beneficial Ownership Statement for Chief Operating Officer Angela Dominy Radkowski"
description: "Tharimmune Inc. has filed an initial beneficial ownership statement (Form 3) with the U.S. SEC, naming Angela Dominy Radkowski as the beneficial owner in her capacity as Chief Operating Officer. The f"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275667782.md"
published_at: "2026-02-11T22:21:26.000Z"
---

# Tharimmune Inc. Files Initial Beneficial Ownership Statement for Chief Operating Officer Angela Dominy Radkowski

> Tharimmune Inc. has filed an initial beneficial ownership statement (Form 3) with the U.S. SEC, naming Angela Dominy Radkowski as the beneficial owner in her capacity as Chief Operating Officer. The filing is accessible through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

Tharimmune Inc. has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission. The filing names Angela Dominy Radkowski as the beneficial owner in her role as Chief Operating Officer. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tharimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-006245), on February 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [THAR.US - Tharimmune](https://longbridge.com/en/quote/THAR.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| US FDA approves first line use of Boehringer Ingelheim's lung cancer drug | The U.S. FDA has approved Boehringer Ingelheim's zongertinib as a first-line treatment for a rare form of non-small cell | [Link](https://longbridge.com/en/news/277082466.md) |
| BUZZ-Tevogen rises on plans to buy majority stake in digital health firm Sciometrix | Shares of drug developer Tevogen Biorise 13.7% to 33 cents premarketCo signs letter of intent to buy a majority stake in | [Link](https://longbridge.com/en/news/277058905.md) |
| Delcath Q4 revenue rises 37%, beats estimates | Delcath Systems reported a 37% increase in Q4 revenue, surpassing analyst expectations with $20.73 million. Despite a ne | [Link](https://longbridge.com/en/news/277046688.md) |
| Soleno Therapeutics reports FY profit for 2025 | Soleno Therapeutics reported a profitable FY 2025 with a net income of $20.9 million, driven by Q4 revenue of $91.7 mill | [Link](https://longbridge.com/en/news/276938001.md) |
| Caris Life Sciences Completes Interim Readout of Achieve 1 Study \| CAI Stock News | Caris Life Sciences has announced an interim readout of its Achieve 1 study, demonstrating the effectiveness of its mult | [Link](https://longbridge.com/en/news/277111732.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.